TCM
MYGN icon

Teza Capital Management’s Myriad Genetics MYGN Stock Holding History

Teza Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,766
Closed -$226K – 715
2023
Q2 		$226K Buy
+9,766
New +$213K 0.04% 481
2020
Q4 		– Sell
-13,211
Closed -$172K – 387
2020
Q3 		$172K Buy
+13,211
New +$167K 0.1% 310
2018
Q2 		– Sell
-20,559
Closed -$608K – 542
2018
Q1 		$608K Sell
20,559
-2,285
-10% -$77.3K 0.15% 254
2017
Q4 		$785K Buy
+22,844
New +$771K 0.47% 94

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Teza Capital Management's MYGN Position: Q3 2023 in Review

Teza Capital Management sold out of Myriad Genetics (MYGN) in Q3 2023, closing a stake of 9,766 shares — an estimated $226K sold.

Teza Capital Management first reported a position in MYGN in Q4 2017 and held it in 4 quarters. The position peaked at $785K in Q4 2017. 186 funds tracked by Wall St. Rank hold MYGN as of Q3 2023.

  • Teza Capital Management reported no remaining Myriad Genetics position as of Q3 2023 after selling out during the quarter.
  • Teza Capital Management sold 9,766 Myriad Genetics shares in Q3 2023, an estimated $226K.
  • Teza Capital Management first reported a position in Myriad Genetics in Q4 2017 and held it in 4 quarters.
  • Teza Capital Management's Myriad Genetics position peaked at $785K in Q4 2017.
  • 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2023.

Based on Teza Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.